Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2018.104 | A Phase 2a, Randomized, Partially-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Pharmacokinetics of Treatment With Multiple Doses of JNJ-56136379 as Monotherapy and in Combination With a Nucleos(t)ide Analog in Subjects With Chronic Hepatitis B Virus Infection |
Prof. CHAN Henry Lik Yuen 陳力元 |
| 2017.530 | A Phase 2, Open-label Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Alafenamide (TAF) from Tenofovir Disoproxil Fumarate (TDF) and/or Other Oral Antiviral Treatment (OAV) in Virologically Suppressed Chronic Hepatitis B Subjects with Renal and/or Hepatic Impairment |
Prof. CHAN Henry Lik Yuen 陳力元 |
| 2016.369 | Sample Collection for the Evaluation of Elecsys® PIVKA-II, AFP-L3 and AFP |
Prof. CHAN Henry Lik Yuen 陳力元 |
| 2015.190 | A Multicenter, Randomized, Double-blind, Placebo-controlled, Multi-dose Study to Determine the Depth of Hepatitis B Surface Antigen (HBsAg) Reduction Following Intravenous ARC-520 in Combination with Entecavir or Tenofovir in Patients with HBeAg Positive, Chronic Hepatitis B Virus (HBV) Infection |
Prof. CHAN Henry Lik Yuen 陳力元教授 |
| 2015.189 | A Multicenter, Randomized, Double-blind, Placebo-controlled, Multi-dose Study to Determine the Depth of Hepatitis B Surface Antigen (HBsAg) Reduction Following Intravenous ARC-520 in Combination with Entecavir or Tenofovir in Patients with HBeAg Negative, Chronic Hepatitis B Virus (HBV) Infection |
Prof. CHAN Henry Lik Yuen 陳力元教授 |
| 2016.350 | A Phase II/III, Open-label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-3682B (MK-3682 + Grazoprevir + MK-8408 Fixed Dose Combination) in Subjects with Chronic Hepatitis C Virus GT5 or GT6 Infection |
Prof. CHAN Henry Lik Yuen 陳力元教授 |
| 2016.529 | Cells of monocytic origin as surrogate marker for individual drug effects and hepatotoxicity |
Prof. CHAN Henry Lik Yuen 陳力元 |
| 2010.336 | A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study of FG-3019 in Subjects with Liver Fibrosis due to Chronic Hepatitis B Infection | Prof. CHAN Henry Lik Yuen |
| 2003.382 | A Randomized, Double-blind Trial of Telbivudine (LdT) versus Lamivudine in Adults with Decompensated Chronic Hepatitis B and Evidence of Cirrhosis | Prof. CHAN Henry Lik Yuen |
| 2013.410 | A Phase 3b, Multicenter, Open-Label, Randomized Study to Investigate the Efficacy and Safety of Sofosbuvir plus Ribavirin in Treatment-Na_ve Subjects with Chronic Genotype 1, 2, 3 and 6 HCV Infection and in Treatment-Experienced Subjects with Chronic Genotype 2 HCV Infection | Prof. CHAN Henry Lik Yuen |
| 2011.233 | A Phase 4, Randomized, Open-label, Active-Controlled, Superiority Study to Evaluate the Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in Combination with Peginterferon α-2a (Pegasys®) versus Standard of Care Tenofovir Disoproxil Fumarate Monotherapy or Peginterferon α-2a Monotherapy for 48 Weeks in Non-Cirrhotic Subjects with HBeAg-Positive or HBeAg-Negative Chronic Hepatitis B (CHB) | Prof. CHAN Henry Lik Yuen |
| 2013.605 | A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After a Single Intravenous Dose of ARC-520 in Combination with Entecavir in Patients with Chronic Hepatitis B Virus (HBV) Infection, followed by a two-dose open label cohort and an open label single dose cohort in treatment naïve patients | Prof. CHAN Henry Lik Yuen |
| 2018.313 | A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple Dose Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AB-506, an HBV Capsid Inhibitor, in Healthy Subjects and HBV-DNA Positive Subjects with Chronic HBV Infection |
Prof. CHAN Henry Lik Yuen 陳力元 |
| 2019.233 | CATALYST 207: A PHASE 2, PILOT, EXPLORATORY STUDY EVALUATING THE SAFETY AND ANTIVIRAL EFFICACY OF INARIGIVIR SOPROXIL IN NON-CIRRHOTIC TREATMENT-NAÏVE SUBJECTS INFECTED WITH CHRONIC HEPATITIS B VIRUS | Prof. CHAN Henry Lik Yuen |
| 2019.151 | A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GS-4224 in Healthy Volunteers and Subjects with the Chronic Hepatitis B (CHB) Virus |
Prof. CHAN Henry Lik Yuen 陳力元教授 |
| 2014.354 | Performance of Fibrometer™ S and V in Chinese patients with non alcoholic fatty liver disease (NAFLD) | Prof. CHAN Henry Lik Yuen |
| 2014.488 | A Phase 1b Dose-Ranging Study to Assess the Safety, Pharmacokinetics and Initial Antiviral Efficacy of NVR 3-778 in Patients with HBeAg-Positive, Chronic Hepatitis B Virus Infection | Dr. CHAN Henry Lik Yuen |
| 2013.694 | Genetic Study of Peginterferon Treatment in Hepatitis B: The GIANT -B Study | Prof. CHAN Henry Lik Yuen |
| 2010.093 | Genetic Variation in IL28B and the response to peginterferon treatment in patients with chronic hepatitis B | Dr Chan Henry Lik-Yuen |
| 2008.164 | Effect of Alcohol and Caffeine on the Severity of Liver Fibrosis in Chronic Hepatitis B | Prof Chan Henry Lik-Yuen |
| 2009.250 | A randomized, open-label, controlled, exploratory trial to characterize the results of daily oral administration of telbivudine 600mg and tenofovir disproxil fumarate 300mg in combination or telbivudine 600mg or tenofovir disproxil furmarate 300mg monothe | Professor Chan Henry Lik-Yuen |
| 2013.156 | A multi-centre 3-year follow-up study to assess the durability of sustained virologic response in Alisporivir-treated chronic Hepatitis C patients | Prof. Chan Henry Lik-Yuen |
| 2009.105 | A Single-arm, Multinational, Two Year Study Evaluating the Efficacy and Safety of Lead-in Telbivudine for 24 Weeks with or without Tenofovir Treatment Intensification in Adult Patients with HBeAg-positive Chronic Hepatitis B | Professor Chan Henry Lik-Yuen |
| 2011.525 | Colorectal Cancer Screening in Diabetes Patients: A case-control Study (DM Colon Study) | Dr. Chan Heyson |
| 2015.083 | Patient Knowledge of Inflammatory Bowel Disease in Area of Rising Incidence |
Dr. CHAN Heyson Chi Hey 陳智曦 |
| 2013.406 | Comparison of upper GI involvement of asymptomatic Crohn's disease patients in Europe and Asia | Dr. CHAN Heyson Chi Hey |
| 2016.113 | Incidence of venous thromboembolism in inflammatory bowel disease patients in Asia |
Dr. CHAN Heyson Chi Hey 陳智曦 |
| 2009.447 | A case series observational study on the clinical application of a surgical robot in otorhinolaryngology, head and neck surgery compared to historical controls | Dr Chan Hing Sang |
| 2019.668 | Association between hospital admission episode and use of potentially inappropriate medication in geriatric patient according to Beers Criteria: a Hong Kong local hospital experience | Ms. CHAN Hiu Ching |
| 2021.626 | Prevalence and determinants of neonatal jaundice in Hong Kong: A population-based, retrospective analysis |
Dr. CHAN Hiu Ying 陳曉瑩 |
| 2023.540 | Effectiveness of MSK Occupational Therapy Program in treating patients with shoulder pain |
Mr. CHAN Ho Man 陳昊旻 |
| 2011.427 | Survelliance of emerging drugs of abuse in substance abusers | Dr CHAN Ho Ming Michael |
| 2013.007 | Determination of optimal holotranscobalamin diagnostic cutoff for vitamin B12 deficiency in local Chinese population - a clinical laboratory evaluation study | Dr. Chan Ho Ming Michael |
| 2011.350 | Study of the system performance of cobas 8000 clinical chemistry analyzer in a hospital-based clinical laboratory | Dr CHAN Ho Ming, Michael |
| 2019.532 | Evaluation of the effectiveness of acupuncture at L.I.11 Quchi acupoint on knee pain in Hong Kong distance runners: A randomized controlled trial |
Ms. Chan Ho Yan 陳可昕 |
| 2018.049 | Improving workflow of Emergency Medicine Ward (EMW) admission process in North District Hospital (NDH) by using self-administered health assessment form |
Miss CHAN Ho Yi 陳可宜 |
| 2019.695 | A prospective pilot study on the effectiveness of MEDFRAT in reducing falls in Hong Kong Emergency Department |
Miss CHAN Ho Yi 陳可宜 |
| 2023.236 | DECT special application in MSK : Case Series | Dr. CHAN Hoi Ling |
| 2023.168 | Pictorial Review of Breast Augmentations and Their Complications | Dr. CHAN Hoi Ling |
| 2023.207 | Transcatheter Arterial Embolization of Renal Angiomyolipoma Using Ethanol and Lipiodol | Dr. CHAN Hoi Ling |
| 2023.169 | Breast Intraductal Papilloma Diagnosed by Core Needle Biopsy: Prognosis of Vacuum-assisted Excision, Surgical Excision or Follow-up USG | Dr. CHAN Hoi Ling |
| 2022.248 | Psychoeducation with active participation for enhancing caregiving self-efficacy among family caregivers of people with dementia: a feasibility trial |
Ms. CHAN Hoi Man 陳海雯 |
| 2014.004 | A cross-sectional study examines the relationships between perceived and actual physical competence, enjoyment and physical activity in Primary School children. | Ms Chan Hoi Sze Cecilica |
| 2010.273 | Correlational Study on catastrophizing and Patient Functioning - the Buffering role of value among Breast Cancer Patients | Ms CHAN Hoi Sze Gloria |
| 2010.269 | Correlational Study on Catastrophizing and Patient Functioning - the Buffering Role of value among Lung Cancer Patients | Ms CHAN Hoi Sze Gloria |
| 2011.279 | Continuous Quality Improvement: Use of Lean Techniques to Improve Patient Flow in Emergency Department | Ms. Chan Hoi Yan |
| 2012.304 | Therapeutic hypothermia after cardiac arrest: a survey of practice in ICUs in Hong Kong | Dr Chan Hok Sum |
| 2011.010 | The management pattern,co-morbidities and morbidity of COPD patients in HK | Dr Chan Hok Sum |
| 2014.555 | Disease Burden of Chronic Obstructive Pulmonary Disease of in-patients in the Hospital Authority in Hong Kong - the Trend from 2006 - 2014 | Dr. CHAN Hok Sum |
| 2014.294 | Patient Registry of Roflumilast In Real Life-Division of North Asia | Dr. CHAN Hok Sum |
Page 56 of 262.